Web Exclusives
Web Exclusives — July 14, 2018
Learn some quick facts, most common types, and signs and symptoms of bone cancer and sarcoma in this slideshow.
Read More ›
Web Exclusives — May 11, 2018
This is the first treatment that targets patients with AML and the FLT3-ITD mutation. In this clinical trial, patients who received quizartinib lived longer without disease progression than those receiving chemotherapy. Read More ›
Web Exclusives — May 1, 2018
May is Skin Cancer Awareness Month! View this slideshow to learn the latest statistics in the United States, leading causes and preventive measures, and quick facts on melanoma, one of the most common types of skin cancer. Conquer cancer with knowledge. Read More ›
Web Exclusives — April 7, 2018
NeuVax + Herceptin may provide a clinically meaningful benefit to breast cancer patients with low to intermediate HER2-expression. Read More ›
Web Exclusives — April 5, 2018
April is Testicular Cancer Awareness Month! Take a cruise through this slideshow full of facts about testicular cancer, such as the common risk factors and symptoms to look out for. Conquer cancer with knowledge. Read More ›
Web Exclusives — March 14, 2018
Lillie Shockney shares a touching, personal story of an experience she had at the Young Survival Coalition Summit, where she held a workshop called “Building Your Legacy." Read More ›
Web Exclusives — March 1, 2018
March is Colorectal Cancer Awareness Month! Flip through this slideshow featuring the top risk factors for colorectal cancer, symptoms to look out for, and more. Conquer cancer with knowledge. Read More ›
Web Exclusives — February 26, 2018
In patients with HR-positive breast cancer, a positive circulating tumor cells assay result was associated with nearly a 20-fold increased risk for recurrence of disease. Read More ›
Web Exclusives — February 26, 2018
Older women with hormone receptor–positive, HER2-negative metastatic breast cancer who are treated with a CDK4/6 inhibitor may derive benefits similar to those seen in their younger counterparts. Read More ›
Web Exclusives — February 26, 2018
Treatment with a regimen of pembrolizumab plus trastuzumab in patients with trastuzumab-resistant advanced HER2-positive breast cancer was well-tolerated and had clinical benefit in those whose tumors were positive for a biomarker for pembrolizumab. Read More ›